4-amino-2,3-dihydroisoindol-1-one

We are 4-amino-2,3-dihydroisoindol-1-one CAS:366452-98-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:4-amino-2,3-dihydroisoindol-1-one
CAS.NO:366452-98-4
Synonyms:4-amino-2,3-dihydroisoindol-1-one
4-Amino-2,3-dihydro-1H-isoindol-1-one
4-amino-1-isoindolinone
4-AMINOISOINDOLIN-1-ONE
 
Physical and Chemical Properties:
Density 1.307 g/cm3
Boiling Point 489.776ºC at 760 mmHg
Melting Point 225-230ºC
Molecular Formula C8H8N2O
Molecular Weight 148.16200
Flash Point 250.008ºC
 
Specification:
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lenalidomide(CAS:191732-72-6).

4-amino-2,3-dihydroisoindol-1-one


Related News: Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.2-nitro-1-N-fenilbenceno-1,4-diamina CAS:2784-89-6 The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.ácido benzo [b] nafto [2,3-d] furan-5-borónico CAS:1256544-85-0 After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API.2,8-bis(trifluoromethyl)-1H-quinolin-4-one Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.

Related Products
Product Name
3,5-Dichloro-2-fluoropyridine View Details
Glycine View Details
Thiophosgene View Details
4-Bromo-2-fluorobenzenesulfonamide manufacturer Suberic Acid Monomethyl Ester manufacturer methyl pyridine-4-carboxylate manufacturer n-butyl isocyanate manufacturer 2-Amino-5-methyl-3-thiophenecarbonitrile manufacturer